Metastasis promoter S100A4 is a potentially valuable molecular target for cancer therapy
Author:
- 1 July 2009
- journal article
- review article
- Published by Elsevier in Cancer Letters
- Vol. 280 (1) , 15-30
Abstract
No abstract availableKeywords
This publication has 131 references indexed in Scilit:
- The ratio of matrix metalloproteinase to E‐cadherin expression: A pilot study to assess mRNA and protein expression among African American prostate cancer patientsThe Prostate, 2008
- MMP-2 geno-phenotype is prognostic for colorectal cancer survival, whereas MMP-9 is notBritish Journal of Cancer, 2008
- Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabineInternational Journal of Cancer, 2008
- Structure of Ca2+-Bound S100A4 and Its Interaction with Peptides Derived from Nonmuscle Myosin-IIABiochemistry, 2008
- Integrin connections to the cytoskeleton through talin and vinculinBiochemical Society Transactions, 2008
- MMPs as therapeutic targets—Still a viable option?Seminars in Cell & Developmental Biology, 2008
- A Biosensor of S100A4 Metastasis Factor Activation: Inhibitor Screening and Cellular Activation DynamicsBiochemistry, 2007
- Epigenetic deregulation of multiple S100 gene family members by differential hypomethylation and hypermethylation events in medulloblastomaBritish Journal of Cancer, 2007
- Wnt Signaling Induces Matrix Metalloproteinase Expression and Regulates T Cell TransmigrationImmunity, 2007
- Mts1 Regulates the Assembly of Nonmuscle Myosin-IIABiochemistry, 2003